• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑癌蛋白 p53 在前列腺癌中的预后意义。

Prognostic significance of tumor suppressor protein p53 in prostate cancer.

机构信息

Department of pathology. Internal security forces hospital, Tunis, Tunisia.

Department of urology. Internal security forces hospital, Tunis, Tunisia.

出版信息

Tunis Med. 2024 Feb 5;102(2):111-115. doi: 10.62438/tunismed.v102i2.4730.

DOI:10.62438/tunismed.v102i2.4730
PMID:38567478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11358809/
Abstract

INTRODUCTION

The p53 gene mutation is one of the most common genetic alterations in many cancers. In prostate cancer (PCa), it has been associated with a poor prognosis, tumor progression and aggressiveness. P53 mutation induces an abnormal protein expression in related tissues.

AIM

This study aimed to assess p53 expression using immunohistochemistry in PCa and to discuss its prognostic value.

METHODS

We have retrospectively collected all cases of PCa diagnosed in our pathology department between 2012 and 2022. An automatized immunohistochemical analysis was performed using monoclonal p53 antibody. For each case, we assessed the proportion of positive cells and the intensity of staining. P53 expression was considered abnormal when it was totally negative or overexpressed (>=50% of positive cells).

RESULTS

Twenty-four cases have been selected. Abnormal p53 expression was found in 42% of cases (P53 was overexpressed in 6cases and totally negative in 4 cases). Mean age of patients with p53 abnormal expression was 70years old. Patients with p53 abnormal expression had Gleason score >7 in 5 cases, ISUP grade >2 in 3 cases, peri-neural invasion in 8cases, capsule invasion in 9cases. All patients with p53 overexpression developed androgen resistance (p<0.01).

CONCLUSION

An aberrant expression profile of the p53 protein was observed in 42% of cases, and a statistically significant association was found with androgen resistance. Our results suggest a potential prognostic role of p53 in PCa.

摘要

简介

p53 基因突变是许多癌症中最常见的遗传改变之一。在前列腺癌(PCa)中,它与预后不良、肿瘤进展和侵袭性有关。p53 突变会导致相关组织中异常蛋白表达。

目的

本研究旨在通过免疫组织化学方法评估 PCa 中 p53 的表达,并探讨其预后价值。

方法

我们回顾性地收集了 2012 年至 2022 年间在我们病理科诊断的所有 PCa 病例。使用单克隆 p53 抗体进行自动免疫组织化学分析。对于每个病例,我们评估了阳性细胞的比例和染色强度。当 p53 表达完全阴性或过表达(>=50%的阳性细胞)时,认为其表达异常。

结果

共选择了 24 例病例。异常 p53 表达在 42%的病例中发现(6 例病例 p53 过表达,4 例病例完全阴性)。p53 表达异常患者的平均年龄为 70 岁。p53 表达异常的患者中有 5 例 Gleason 评分>7,3 例 ISUP 分级>2,8 例有神经周围侵犯,9 例有包膜侵犯。所有 p53 过表达的患者均发生雄激素抵抗(p<0.01)。

结论

在 42%的病例中观察到 p53 蛋白表达异常,与雄激素抵抗有统计学显著关联。我们的结果表明 p53 在 PCa 中可能具有潜在的预后作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/214b424f44fb/capture4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/680ef4f4b9a6/capture1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/2d07acfb9161/capture2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/69c439f307de/capture3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/214b424f44fb/capture4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/680ef4f4b9a6/capture1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/2d07acfb9161/capture2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/69c439f307de/capture3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5683/11358809/214b424f44fb/capture4.jpg

相似文献

1
Prognostic significance of tumor suppressor protein p53 in prostate cancer.抑癌蛋白 p53 在前列腺癌中的预后意义。
Tunis Med. 2024 Feb 5;102(2):111-115. doi: 10.62438/tunismed.v102i2.4730.
2
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.局部晚期前列腺腺癌的p53状态与预后:一项基于RTOG 8610的研究
J Natl Cancer Inst. 1997 Jan 15;89(2):158-65. doi: 10.1093/jnci/89.2.158.
3
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.细胞因子信号转导抑制因子1(SOCS1)及其假定的肿瘤抑制功能下游靶点在前列腺癌中的表达
BMC Cancer. 2017 Feb 24;17(1):157. doi: 10.1186/s12885-017-3141-8.
4
Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.前列腺癌和前列腺上皮内瘤变中p53蛋白的免疫组织化学测定
Urol Int. 1997;58(4):199-202. doi: 10.1159/000282983.
5
Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.免疫组织化学检测p53蛋白作为前列腺癌的预后指标
Rom J Morphol Embryol. 2006;47(2):143-6.
6
Clinical significance of p53 alterations in surgically treated prostate cancers.手术治疗前列腺癌中p53改变的临床意义
Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.
7
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.p53蛋白积累与基因突变在人类前列腺癌进展中的作用
J Natl Cancer Inst. 1993 Oct 20;85(20):1657-69. doi: 10.1093/jnci/85.20.1657.
8
Differential CARM1 expression in prostate and colorectal cancers.前列腺癌和结直肠癌中 CARM1 的差异表达。
BMC Cancer. 2010 May 13;10:197. doi: 10.1186/1471-2407-10-197.
9
[P53 expression and its clinical significance in prostatic carcinoma].[P53在前列腺癌中的表达及其临床意义]
Zhonghua Nan Ke Xue. 2005 Jun;11(6):448-51, 454.
10
SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.SOCS3免疫组化表达似乎支持2005年和2014年国际泌尿病理学会(ISUP)改良的Gleason分级系统。
Prostate. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1.

引用本文的文献

1
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy-A Narrative Review.蛋白质在肿瘤学中的作用:癌症诊断、预后及靶向治疗的进展——一篇叙述性综述
J Clin Med. 2024 Nov 25;13(23):7131. doi: 10.3390/jcm13237131.
2
Polygenic anti-cancer activity of in prostate cancer induced animal model.在前列腺癌诱导动物模型中[物质名称]的多基因抗癌活性 。 (原文中“of”后面缺少具体内容,这里翻译只能做到根据已有内容尽可能准确表述)
Toxicol Rep. 2024 Oct 22;13:101774. doi: 10.1016/j.toxrep.2024.101774. eCollection 2024 Dec.

本文引用的文献

1
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.原发前列腺肿瘤中局灶性 p53 蛋白表达和淋巴管侵犯预测转移进展。
Sci Rep. 2022 Mar 30;12(1):5404. doi: 10.1038/s41598-022-08826-5.
2
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.TP53 或 DNA 损伤修复基因的突变定义了原发性前列腺癌中预后不良的亚组。
Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26.
3
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
超越雄激素受体:序列、突变体以及在去势抵抗性转移性前列腺癌治疗中的新策略。
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e190-e202. doi: 10.1200/EDBK_321209.
4
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.雄激素受体依赖性机制介导前列腺癌的耐药性。
Cancers (Basel). 2021 Mar 26;13(7):1534. doi: 10.3390/cancers13071534.
5
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.治疗初治转移性前列腺癌男性中 DNA 损伤修复基因缺陷和 TP53 改变的高发率——使用 37 基因panel 的前瞻性初步研究结果。
Urol Oncol. 2020 Jul;38(7):637.e17-637.e27. doi: 10.1016/j.urolonc.2020.03.001. Epub 2020 Apr 10.
6
Genomics of lethal prostate cancer at diagnosis and castration resistance.诊断时致命性前列腺癌和去势抵抗性前列腺癌的基因组学
J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031.
7
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.转移性去势抵抗性前列腺癌的基因组图谱揭示了多种具有潜在临床影响的独特基因型。
Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
8
Epidemiology of Prostate Cancer.前列腺癌流行病学
World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
9
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.局部和转移性前列腺癌中 TP53、PTEN 和 RB1 肿瘤抑制因子的复合基因组改变。
Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.
10
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.原发肿瘤中 p53 的状态可预测后续阿比特龙和恩杂鲁胺在去势抵抗性前列腺癌中的疗效。
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):260-268. doi: 10.1038/s41391-017-0027-4. Epub 2018 Jan 4.